CSIMarket Company Name, Ticker, Competitors, else..
 
Opgen Inc   (NASDAQ: OPGN)
Other Ticker:  
 
    Sector • Healthcare    Industry • Medical Laboratories
   Industry • Medical Laboratories
   Sector • Healthcare
 
Price: $1.8500 $0.18 10.778%
Day's High: $1.85 Week Perf: 54.17 %
Day's Low: $ 1.80 30 Day Perf: 54.17 %
Volume (M): 2 52 Wk High: $ 9.90
Volume (M$): $ 4 52 Wk Avg: $2.57
Open: $1.83 52 Wk Low: $0.53



 Market Capitalization (Millions $) 2
 Shares Outstanding (Millions) 1
 Employees 22
 Revenues (TTM) (Millions $) 2
 Net Income (TTM) (Millions $) -22
 Cash Flow (TTM) (Millions $) -3
 Capital Exp. (TTM) (Millions $) 0

Opgen Inc
OpGen Inc. is a biotechnology company that specializes in developing molecular testing and bioinformatics solutions for infectious diseases. The company was founded in 2001 and is headquartered in Gaithersburg, Maryland, United States.

OpGen's primary focus is on combating antibiotic resistance by providing tools for rapid and accurate identification of pathogens and their antibiotic resistance profiles. Their flagship product, Acuitas' Lighthouse, is a genomic surveillance solution that enables hospitals and labs to track and analyze bacterial genomes to better understand and respond to outbreaks.

In addition to Acuitas Lighthouse, OpGen also offers other products and services, including Acuitas' AMR Gene Panel tests for antibiotic resistance detection, Acuitas' Rapid Test kits for detecting pathogen DNA, and Acuitas' Resistome Test kits for comprehensive pathogen profiling.

The company's innovative technologies integrate molecular testing, bioinformatics, and data management to enable faster and more accurate identification of pathogens, leading to improved patient outcomes and more effective infection control practices.

OpGen Inc. collaborates with various healthcare institutions, pharmaceutical companies, and governmental organizations to further develop and validate their products. They have received several grants and awards for their contributions to the field of infectious disease diagnostics.

Overall, OpGen Inc. strives to advance the fight against antibiotic resistance by providing innovative molecular testing and bioinformatics solutions that help healthcare professionals make more informed treatment decisions.


   Company Address: 23219 Stringtown Road Clarksburg 20871 MD
   Company Phone Number: 813-1260   Stock Exchange / Ticker: NASDAQ OPGN


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ENZ        10.11% 
EXAS   -1.55%    
FTRE   -0.7%    
GH        0.19% 
NTRA        6.59% 
PSNL        6% 
• View Complete Report
   



Opgen Inc

Opgen Inc Announces Financial Success with the Transition to Profitability in Medical Laboratories Division

Recently released financial data from OpGen Inc. shows that the company has seen a significant turnaround in its financial performance for the fiscal interval closing March 31, 2024. The company reported earnings per share of $0.21, a substantial improvement from the negative $12.50 per share reported in the same period a year prior. Furthermore, net profit per share turned positive, going from a negative $14.31 per share to a positive $0.273 million in the most recent reporting season.
However, despite these improvements in earnings, OpGen Inc. experienced a steep decline in revenue, with a decrease of -81.592% to $0.17 million from $0.91 million in the same reporting season a year prior. Sequentially, revenue tumbled even further by -84.281% from $1.07 million. This decrease in revenue may be cause for concern for investors and analysts.
Announcement

OpGen Faces Potential Delisting from Nasdaq as Noncompliance Notice Is Issued

Published Fri, May 24 2024 8:05 PM UTC

Content:OpGen, a Maryland-based biotechnology company listed on the Nasdaq exchange under the ticker symbol OPGN, has recently received a notice from The Nasdaq Stock Market LLC. The notice states that OpGen is not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires timely filing of all periodic reports with the Securities and Exchange Commission (SEC). The sp...
Shares

OpGen Announces Reverse Stock Split: Analyzing the Impact on Share Price

Published Thu, May 16 2024 11:00 AM UTC

OpGen Announces Reverse Stock Split: What Investors Need to Know
OpGen, Inc. (Nasdaq: OPGN) recently announced a 1-for-10 reverse stock split of its shares of common stock, which will become effective on May 20, 2024. This decision, approved by the company s board of directors, will result in the company s common stock trading on The Nasdaq Capital Market on a post-split...
Merger and Acquisition

OpGen's Sale of Unyvero Systems Marks Strategic Shift

Published Mon, Apr 29 2024 8:05 PM UTC


Rockville-based molecular diagnostics company, OpGen Inc. (Nasdaq: OPGN) has recently announced the sale of its commercial customer contracts and installed base of Unyvero systems to Singaporean family office, Camtech Pte Ltd. The deal, worth $218,000, comes as part of OpGen s larger strategic move in light of the insolvency proceedings of its subsidiary, Curetis.
O...
Shares

OpGen Secures $3 Million Investment to Repay Debts and Drive Growth

Published Mon, Mar 25 2024 8:05 PM UTC

OpGen Secures $3 Million Investment from Private Investor to Address Debt and Advance Operations
ROCKVILLE, Md., March 25, 2024 - OpGen, Inc. (Nasdaq: OPGN), a leading precision medicine company harnessing the power of molecular diagnostics, announced today a securities purchase agreement with private investor David E. Lazar. Under the agreement, Lazar will acquire 3,000...






Opgen Inc's Segments





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com